General

Cell Line

hPSCreg name ICGi032-A
Cite as:
ICGi032-A (RRID:CVCL_B3RR)
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
RGIe116-A
(SI-214)
Donor diseases:
Fragile X syndrome
INSRMe016-A
(STR-I-347-FRAXA)
Donor diseases:
Fragile X syndrome
RGIe041-A
(SI-125)
Donor diseases:
Fragile X syndrome
INSRMe005-A
(STR-I-189-FRAXA)
Donor diseases:
Fragile X syndrome
HUJIe001-A
(HEFX1)
Donor diseases:
Fragile X syndrome
VUBe013-A
(VUB13_FXS)
Donor diseases:
Fragile X syndrome
WISi006-A
(FX1 iPSC)
Donor's gene variants:
FMR1
Donor diseases:
Fragile X syndrome
INSRMe002-A
(STR-I-233-FRAXA)
Donor diseases:
Fragile X syndrome
HADe005-A
(HAD 5)
Donor diseases:
Fragile X syndrome
VUBe011-A
(VUB11_FXS)
Donor diseases:
Fragile X syndrome
Last update 30th November 2021
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences (ICG)

External Databases

BioSamples SAMEA9652840
Cellosaurus CVCL_B3RR
Wikidata Q110432905

General Information

Publications
* Is the cell line readily obtainable for third parties?
No

Donor Information

General Donor Information

Sex male
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
Synonyms
  • Fragile X Syndrome

Karyotyping (Donor)

Has the donor karyotype been analysed?
Unknown

External Databases (Donor)

BioSamples SAMEA9652841

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? Yes

Does consent permit research by

an academic institution? Yes
a public organisation? No
a non-profit company? No
a for-profit corporation? No
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Ethics Committee of State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being.
Approval number RSF 18-15-00099
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Ethics Committee of State Research Center of Virology and Biotechnology “Vector”, Federal Service for Surveillance on Consumer Rights Protection and Human Well-being.
Approval number RSF 18-15-00099
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell line name CPG18
Source cell type
Synonyms
  • EBV-Transformed Mature B-Lymphocyte

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No
Methods used
PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Gelatin
Feeder cells mouse embryonic fibroblast cell
Passage method Mechanically
CO2 Concentration 5 %
Medium Other medium:
Base medium: DMEM/F12
Main protein source: Knock-out serum replacement
Serum concentration: 20 %
Supplements
Pen Strep 1 %
GlutaMAX 1 %
MEM Non-essential Amino Acid 1 %
2-mercaptoethanol 0.1 mM
bFGF 10 ng/ml
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SSEA-4
Yes
NANOG
Yes
TRA 1-60
Yes
SOX2
Yes
Morphology pictures
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
AFP
Yes
SOX17
Yes
HNF1A
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
MSX1
Yes
FLK1
Yes
TBXT
Yes
Ectoderm
Ont Id: UBERON_0000924
Marker Expressed
PAX6
Yes
SOX1
Yes
MAP2
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XY
Passage number: 12
Karyotyping method: G-Banding

Other Genotyping (Cell Line)